Search the Newsreel

Understanding Momentum Shifts in (VLTO)

This article analyzes Veralto Corp (NASDAQ: VLTO) using AI models to identify momentum shifts and provide trading strategies. Key findings indicate mixed sentiment across different time horizons and no clear resistance levels above the current price, suggesting potential upside. Three distinct institutional trading strategies—Position …

Monster Rises 3.6% Following Stock Split; 40x Earnings Pace Scrutinized Amid Higher Marketing Spend

VRXA: Veraxa Biotech AG - Comparison to Industry

Why Veralto (VLTO) Is Back In The Spotlight

Veralto (VLTO) is gaining investor attention due to improved earnings estimates, a positive outlook driven by U.S. infrastructure and semiconductor demand, and its recent acquisition of In-Situ Inc. While the stock's share price has seen recent positive momentum, its P/E ratio is currently above …

Molson Coors’s Q2 Earnings Call: Our Top 5 Analyst Questions

Molson Coors's Q2 Earnings Call: Our Top 5 Analyst Questions Molson Coors' Q2 results were shaped by external pressures that weighed on sales and profitability, with revenue meeting Wall Street's expectations but operating margin declining significantly from the prior year. Management attributed the performance …

5 Insightful Analyst Questions From Monster’s Q2 Earnings Call

5 Insightful Analyst Questions From Monster's Q2 Earnings Call Monster's second-quarter performance was marked by robust top-line growth, as revenue exceeded Wall Street's expectations, but the market responded negatively, reflecting concerns about profitability and expense trends. Management attributed the quarter's strong sales to broad-based …

Verastem (NASDAQ:VSTM) Stock Rating Lowered by Wall Street Zen

Wall Street Zen downgraded Verastem (NASDAQ:VSTM) from "hold" to "sell," despite the broader analyst consensus remaining a "Moderate Buy" with an average price target of $13.83. The biopharmaceutical company recently exceeded quarterly earnings expectations, reporting a loss of $0.35 per share against an estimated …

Veradermics (MANE) holder SR One sells 321,749 shares, cuts stake to 4.9%

SR One-affiliated funds have reduced their stake in Veradermics (MANE) by selling 321,749 common shares at $104.30 per share, totaling approximately $33.5 million. Following this transaction, SR One's combined holdings represent 4.9% of Veradermics' outstanding common stock, bringing their beneficial ownership below the 5% …

Veracyte Inc (VCYT) Shares Fall 3.2% -- GF Value Says Still Overvalued

Veracyte Inc (VCYT) shares dropped 3.2% to $41.25, placing it 6.7% overvalued compared to its GF Value™ of $38.65, despite a strong GF Score™ of 80/100. Insider selling totaling $9.7 million over the past three months, with no reported buying, suggests caution for potential …

Veradermics (MANE) director-linked trusts sell 100,000 shares of common stock

Entities linked to Veradermics director John W. Childs sold 100,000 shares of common stock on August 12, 2026, through indirect holdings. These sales were conducted via the John W. Childs 2013 Revocable Trust and J.W. Childs Associates (FL), L.P., at weighted-average prices ranging from …

Vera Therapeutics Shares Up 9.7% as $425,000 Drug Launch Puts Focus on Cash Reserves

Kynam Capital (VERA) now holds 4.01% beneficial stake in Vera Therapeutics

Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang have reported a 4.01% beneficial ownership stake in Vera Therapeutics, Inc. Class A common stock. This represents 2,890,059 shares with shared voting and dispositive power. The filing indicates that their ownership is …

China Resources Beverage Sets Board Meeting to Approve Interim Results and Consider Dividend

Vera Therapeutics (NASDAQ:VERA) Shares Gap Up - Here's Why

T. Rowe Price Investment Management (VLTO) discloses 5.6% Veralto Corp stake

T. Rowe Price Investment Management has disclosed a 5.6% stake in Veralto Corp (VLTO), amounting to 13,722,619 shares of common stock as of June 30, 2026. This ownership, reported via a Schedule 13G filing, indicates sole voting power over 13,257,448 shares and sole dispositive …

Verastem, Inc. (VSTM) sees 7.76% ownership reported by Armistice Capital

Armistice Capital, LLC and Steven Boyd have reported a significant beneficial ownership stake of 7.76% in Verastem, Inc. (VSTM), totaling 7,024,000 shares. This ownership is held with shared voting and dispositive power through Armistice Capital Master Fund Ltd., where Armistice Capital acts as the …

HC Wainwright Has Positive Estimate for VERA Q3 Earnings

We Think Veradermics (NYSE:MANE) Can Afford To Drive Business Growth

Monster Beverage (NASDAQ:MNST): Strong Growth Meets a Promising Technical Setup

LiveRamp Holdings (RAMP) Could Be 7% Undervalued Following First Quarter Results

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. LiveRamp Holdings (RAMP) drew investor attention after reporting first quarter results to June 30, 2026, with sales of US$213.99 million and net income …

VBL Share Price Today - Varun Beverages Stock Analysis

Is Vera Therapeutics (VERA) Undervalued On FDA Approval For TRUTAKNA?

Vera Therapeutics (VERA) received accelerated FDA approval for TRUTAKNA for IgA nephropathy, but its share price has fallen recently despite strong long-term returns. The company is currently loss-making and trades at a P/B ratio of 5.4x, which is below peers but above the broader …

Is Weaker Q2 Earnings Amid Buybacks Altering The Investment Case For Molson Coors (TAP)?

Monster (MNST) Q2 2026 Earnings Call Transcript

Verastem (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) reported strong Q2 2026 results, with net product revenue of $25.1 million and total revenue of $40.1 million. The company secured $75 million in non-dilutive royalty financing and a $15 million milestone payment, extending its cash runway into the second half of …

LiveRamp (RAMP) director Vivian Chow receives 1,058-share equity grant

LiveRamp Holdings, Inc. director Vivian Chow received an equity grant of 1,058 shares of common stock on August 12, 2026, as part of her compensation for service. These shares were issued at $0.00 per share, increasing her directly held position to 31,263 shares. The …

LiveRamp Director Vivian Chow Awarded 1,058 Shares as Part of Board Compensation

Vivian Chow, a director at LiveRamp Holdings, Inc. (NYSE: RAMP), received 1,058 shares of common stock on August 12, 2026, as compensation for her board service. This transaction increases her direct beneficial ownership to 31,263 shares. The shares were granted at no cost, indicating …

LiveRamp Holdings (RAMP) director granted 1,058-share equity award

LiveRamp Holdings, Inc. director Debora B. Tomlin was granted an equity compensation award of 1,058 shares of common stock on August 12, 2026, as part of her compensation for board service. These shares were issued at $0.00 per share, increasing her directly held stake …

LiveRamp (RAMP) director Timothy Cadogan awarded 1,058 common shares as compensation

LiveRamp Holdings, Inc. director Timothy R. Cadogan was granted 1,058 shares of common stock as part of his compensation for board service, increasing his direct holdings to 62,157 shares. The shares were awarded at $0.00 per share, as detailed in a recent Form 4 …

Spotting Winners: Molson Coors (NYSE:TAP) And Beverages, Alcohol, and Tobacco Stocks In Q2

Spotting Winners: Molson Coors (NYSE:TAP) And Beverages, Alcohol, and Tobacco Stocks In Q2 Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let's have a look at Molson Coors (NYSE:TAP) and its peers. These companies' …

Monster Beverage Corp. stock outperforms competitors on strong trading day

Shares of Monster Beverage Corp. (MNST) rose 1.52% to $46.68 on Thursday, outperforming the broader market as the S&P 500 Index and Dow Jones Industrial Average also saw gains. This marked the second consecutive day of increases for the stock. The article highlights Monster …

Veracyte Debuts Prosigna Breast Test in the U.S.

Veracyte Inc. has launched its Prosigna Breast Risk of Recurrence (ROR) test in the U.S. This genomic assay helps patients with early-stage hormone-receptor positive breast cancer determine their 10-year risk of distant recurrence, guiding personalized treatment decisions, including whether chemotherapy will be beneficial. The …

Molson Coors (TAP) Q2 2026 Earnings Call Transcript